Deferasirox--an oral agent for chronic iron overload (Q33245186)

24 July 2017

1 reference

title

Deferasirox--an oral agent for chronic iron overload (English)

1 reference

24 July 2017

1 reference

Heidi E Vanorden

1

1 reference

PubMed ID

16735647

24 July 2017

Tracy M Hagemann

series ordinal

2

1 reference

PubMed ID

16735647

24 July 2017

language of work or name

English

0 references

publication date

30 May 2006

1 reference

Annals of Pharmacotherapy

24 July 2017

1 reference

24 July 2017

40

1 reference

24 July 2017

6

1 reference

24 July 2017

1110-1117

1 reference

Practical management of iron overload.

24 July 2017

1 reference

Complications of beta-thalassemia major in North America

21 January 2018

1 reference

Serum ferritin, liver iron stores, and liver histology in children with thalassaemia

21 January 2018

1 reference

Thalassemia: current approach to an old disease

21 January 2018

1 reference

Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia

21 January 2018

1 reference

21 January 2018

The beta-thalassemias

1 reference

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

21 January 2018

1 reference

Iron-chelating therapy with the new oral agent ICL670 (Exjade).

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G566

1 reference

24 July 2017

1 reference

PubMed ID

16735647